SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus’ arm Etna Biotech to donate $240,000 to National Institutes of Health

23 Apr 2015 Evaluate

Zydus’ Vaccine R & D subsidiary -- Etna Biotech -- announced a collaborative program with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health- for advancing leishmaniasis research. Under a separate gift agreement, Etna Biotech also extended its support of the NIH leishmaniasis program by donating $240,000 for research.

The program’s goal is to collaborate between NIAID's Vector Molecular Biology Section and Etna Biotech, the Vaccine Research Center of Zydus in Italy, to investigate the importance of vector salivary proteins in a future leishmaniasis vaccine, and testing in natural models of parasite transmission a combination of Leishmania antigens with a sand fly salivary protein to develop a novel candidate vaccine against visceral leishmaniasis (VL).

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×